Details for Patent: 11,285,129
✉ Email this page to a colleague
Which drugs does patent 11,285,129 protect, and when does it expire?
Patent 11,285,129 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has one hundred and forty-seven patent family members in twenty-three countries.
Summary for Patent: 11,285,129
Title: | Treatment of circadian rhythm disorders |
Abstract: | Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
Inventor(s): | Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
Assignee: | VANDA PHARMACEUTICALS INC. (Washington, DC) |
Application Number: | 17/368,160 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,285,129
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS | ⤷ Sign Up | |||
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS | ⤷ Sign Up | |||
Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,285,129
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2013211878 | ⤷ Sign Up | |||
Australia | 2013211880 | ⤷ Sign Up | |||
Australia | 2013361459 | ⤷ Sign Up | |||
Australia | 2015206797 | ⤷ Sign Up | |||
Australia | 2016204178 | ⤷ Sign Up | |||
Australia | 2016204217 | ⤷ Sign Up | |||
Australia | 2018201302 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |